# A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

> **NCT02727699** · PHASE2 · COMPLETED · sponsor: **Actinogen Medical** · enrollment: 185 (actual)

## Conditions studied

- Dementia, Alzheimer Type

## Interventions

- **DRUG:** Xanamem™
- **DRUG:** Placebo (for Xanamem™)

## Key facts

- **NCT ID:** NCT02727699
- **Lead sponsor:** Actinogen Medical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-23
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-03-15
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2025-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02727699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02727699, "A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02727699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*